US2011165242A1PendingUtilityA1

In situ gelling drug delivery system

53
Assignee: PSIVIDA INCPriority: Jun 26, 2003Filed: Aug 27, 2010Published: Jul 7, 2011
Est. expiryJun 26, 2023(expired)· nominal 20-yr term from priority
Inventors:Dongling SuPaul AshtonJianbing Chen
A61P 43/00A61P 25/04A61K 47/55A61K 31/485A61K 31/196A61K 9/0051A61K 47/6903A61K 9/0092A61K 9/06A61K 9/0024A61K 31/382A61K 31/542A61K 47/60A61K 47/34
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered.

Claims

exact text as granted — not AI-modified
1 . A sustained release injectable pharmaceutical composition comprising:
 (a) a prodrug, comprising a drug substance covalently linked to a polyoxyethylene ether; and   (b) a biocompatible and bioerodable poly(DL-lactide-glycolide) (PLGA) polymer;   (c) wherein the prodrug serves as a solvent for the PLGA polymer and the PLGA polymer is dissolved in the prodrug; and   (d) wherein the composition forms a gel phase when said composition comes into contact with water or bodily fluids.   
     
     
         2 . A method for forming a polymeric sustained-release drug delivery gel in a subject, comprising injecting into the subject a composition according to any one of  claim 1 . 
     
     
         3 . A method of administering a composition according to  claim 1  wherein the composition is co-administered with an aqueous fluid. 
     
     
         4 . The method according to  claim 3  wherein the aqueous fluid is buffered saline. 
     
     
         5 . A drug delivery device containing a composition according to  claim 1 . 
     
     
         6 . A device according to  claim 5  wherein the device has at least one opening. 
     
     
         7 . A device according to  claim 5  wherein the device is an open tube. 
     
     
         8 . The composition of  claim 1 , wherein the polyoxyethylene ether is polyethylene glycol (PEG). 
     
     
         9 . The composition of  claim 8 , wherein the average MW of the polyethylene glycol is between about 100 and about 6000. 
     
     
         10 . The composition of  claim 8 , wherein the average MW of the polyethylene glycol is between about 200 and about 400.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.